In a study from Iceland, investigators compared GI bleeding rates among 3217 patients receiving rivaroxaban, 2157 receiving apixaban, and 494 receiving dabigatran. Patients were excluded
rivaroxaban
rivaroxaban
Rivaroxaban Again Shown to Cause More GI Bleeding Than Other Direct Oral Anticoagulants
Rivaroxaban Again Shown to Cause More GI Bleeding Than Other Direct Oral Anticoagulants
Want To Take Out Polyps in Anticoagulated Patients? New Data Indicate Apixaban Is the Drug To Be On
Want To Take Out Polyps in Anticoagulated Patients? New Data Indicate Apixaban Is the Drug To Be On
This retrospective cohort study evaluated postpolypectomy bleeding and thromboembolism risks with warfarin, apixaban, dabigatran, and rivaroxaban use in Hong Kong public hospitals between January 2012
